Sunday, June 01, 2025 5:45:20 PM
Recent RNAZ News
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 01/07/2026 05:38:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/06/2026 01:04:38 PM
- TransCode Therapeutics Announces Publication of Preclinical Data Supporting Therapeutic Potential of TTX-MC138 in Glioblastoma • PR Newswire (US) • 01/06/2026 01:01:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/23/2025 09:17:28 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 12/23/2025 09:15:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/22/2025 01:13:34 PM
- TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors • PR Newswire (US) • 12/22/2025 01:01:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/12/2025 09:17:03 PM
- TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial • PR Newswire (US) • 12/11/2025 01:05:00 PM
- TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer • PR Newswire (US) • 11/17/2025 01:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:03:02 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/27/2025 01:07:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2025 01:03:49 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/17/2025 09:10:23 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 10/17/2025 09:09:03 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 12:11:31 PM
- TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO • PR Newswire (US) • 10/14/2025 12:06:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/08/2025 08:26:33 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 10/08/2025 08:13:22 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/08/2025 02:51:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/08/2025 01:57:46 PM
- TransCode Therapeutics shares surge 50% after acquiring Polynoma and securing $25 million financing • IH Market News • 10/08/2025 12:58:45 PM
Rainmaker Worldwide Inc. Announces Settlement Agreement Resolving Legacy Debt Obligation • RAKR • Jan 15, 2026 10:35 AM
Xalles Holdings Announces Management Changes • XALL • Jan 12, 2026 8:46 AM
One World Products Enters 2026 Positioned for Disciplined Growth as Isiah Enterprises • OWPC • Jan 8, 2026 12:22 PM
ConnectM Acquires 40% of Sun Solar, Strengthening Balance Sheet and Expanding National Solar & Storage Footprint in Multi-Billion Dollar U.S. Residential Solar & Storage Market • CNTM • Jan 7, 2026 9:00 AM
EVTV Executes Transformational AZIO AI Acquisition Framework at $3.00 Per Share • EVTV • Jan 6, 2026 7:00 AM
Fifty1 Labs, Inc. Clarifies Status Regarding Previously Announced Collaboration with LUNR Aerospace • FITY • Jan 5, 2026 1:00 PM
